Buy Rating Affirmed for Axsome Therapeutics Amidst Anticipated Clinical Data and Resilient Product Performance

TipRanksApr 26 14:10

Neurocrine Biosciences Upgraded at Wells Fargo on Pipeline

Seeking AlphaApr 24 23:59

Auvelity's Strong Performance Sustains Buy Rating for Axsome Therapeutics

TipRanksApr 16 14:56

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is On The Mark

When you see that almost half of the companies in the Pharmaceuticals industry in the United States have price-to-sales ratios (or "P/S") below 2.9x, Axsome Therapeutics, Inc. (NASDAQ:AXSM) looks to be giving off strong sell signals with its 12.1x P/S ratio.

Simply Wall StApr 15 20:37

Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting

PDF Version AXS-05 in Alzheimer's disease agitation data featured in oral plenary sessionNew data for AXS-07 in migraine demonstrating efficacy in pooled analysisPresentations on cognitive and wa

Axsome TherapeuticsApr 15 12:00

Cantor Fitzgerald Inc.: The Axsome Therapeutics (AXSM.US) rating was reaffirmed and adjusted from an increase holdings to an increase rating, with a target price of $107.00.

Cantor Fitzgerald Inc.: The Axsome Therapeutics (AXSM.US) rating was reaffirmed and adjusted from an increase holdings to an increase rating, with a target price of $107.00.

Zhitong FinanceApr 10 21:41